In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AstraZeneca’s Seasoned Dealmaker Grady On Strategy To Grow Pipeline

Executive Summary

AstraZeneca’s Shaun Grady is an affable dealmaker whose talents – honed over three decades inside the group – are being put to the test as global business development head to help ensure Britain’s second-biggest drugmaker can successfully transform itself, its therapy focus and pipeline. He tells In Vivo about his role leading AZ’s transaction execution, due diligence and alliance and integration management, while overseeing its collaborative “externalization” program, licensing and partnering, M&A and divestments.

Advertisement

Related Content

Sanofi Pasteur, AstraZeneca Link To Develop MEDI8897 Infant RSV Vaccine
MedImmune, Abpro’s Unspecific Plans For Bispecific Antibody Collaboration
AstraZeneca Looks To Insmed To Advance AZD7986 In Bronchiectasis
2016 Pharma Dealmaking: Waiting On The High-Value Deals
AstraZeneca Sells Small-Molecule Antibiotics To Pfizer But Still Investing In R&D
AstraZeneca Hands LEO Dermatology Potential
Big Pharma, UK Universities Launch 'Unique' Early Drug Development Fund
AZ’s Make Or Break Moment Comes Down To Business Development
Bristol And AstraZeneca Make A Splash In Diabetes With Joint Purchase Of Amylin
AstraZeneca Rebuilds R&D Amid Growing Near-Term Pressures

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV004921

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel